IL159388A0 - Improved chelator conjugates - Google Patents

Improved chelator conjugates

Info

Publication number
IL159388A0
IL159388A0 IL15938802A IL15938802A IL159388A0 IL 159388 A0 IL159388 A0 IL 159388A0 IL 15938802 A IL15938802 A IL 15938802A IL 15938802 A IL15938802 A IL 15938802A IL 159388 A0 IL159388 A0 IL 159388A0
Authority
IL
Israel
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
IL15938802A
Other languages
English (en)
Original Assignee
Amersham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Plc filed Critical Amersham Plc
Publication of IL159388A0 publication Critical patent/IL159388A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL15938802A 2001-07-10 2002-07-10 Improved chelator conjugates IL159388A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
PCT/GB2002/003168 WO2003006070A2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
IL159388A0 true IL159388A0 (en) 2004-06-01

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15938802A IL159388A0 (en) 2001-07-10 2002-07-10 Improved chelator conjugates

Country Status (21)

Country Link
US (2) US7597875B2 (xx)
EP (1) EP1404377B1 (xx)
JP (1) JP5015409B2 (xx)
KR (1) KR100892009B1 (xx)
CN (4) CN101537190A (xx)
AT (1) ATE304866T1 (xx)
AU (1) AU2002317317B2 (xx)
BR (1) BR0210965A (xx)
CA (1) CA2450690C (xx)
DE (1) DE60206272T2 (xx)
DK (1) DK1404377T3 (xx)
ES (1) ES2250671T3 (xx)
GB (1) GB0116815D0 (xx)
HK (1) HK1064585A1 (xx)
HU (1) HU228850B1 (xx)
IL (1) IL159388A0 (xx)
MX (1) MXPA04000210A (xx)
NO (1) NO334093B1 (xx)
RU (1) RU2298012C2 (xx)
WO (1) WO2003006070A2 (xx)
ZA (1) ZA200400143B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
CA2452923C (en) * 2001-07-10 2012-02-07 Amersham Health As Peptide-based compounds for targeting integrin receptors
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
WO2005049095A2 (en) 2003-11-24 2005-06-02 Amersham Health As Contrast agent imaging angiotensin ii receptors
US7763234B2 (en) * 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds
RU2007118385A (ru) 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
ATE547388T1 (de) * 2005-06-08 2012-03-15 Ge Healthcare Ltd Verfahren zur verwendung von ä11cükohlenmonoxid zur markierenden synthese von 11c-markierten estern durch sensibilisierte photoinduzierte radikalische carbonylierung
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
WO2007094683A1 (en) 2006-02-15 2007-08-23 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
ATE471724T1 (de) * 2006-12-11 2010-07-15 Ge Healthcare As Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung
CA2745495C (en) 2008-12-02 2017-07-18 The University Of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
CN107362376A (zh) * 2010-07-27 2017-11-21 通用电气健康护理有限公司 放射性药物组合物
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
AU2014216515A1 (en) * 2013-02-15 2015-10-08 Thomas Jefferson University Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
CN112840025A (zh) 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
CA3100235A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
US5997843A (en) 1993-08-04 1999-12-07 Amersham International Plc Radiometal complexes that localise in hypoxic tissue
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
KR960700986A (ko) * 1994-01-12 1996-02-24 네나드 토모브-그리소고노 리간드 및 이들의 금속착체(ligands and metal complexes thereof)
WO1999060018A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (fr) 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Encre d'impression a jet d'encre, procede de production de l'encre, cartouche d'encre et dispositif d'impression comportant cette encre

Also Published As

Publication number Publication date
DK1404377T3 (da) 2006-01-30
KR20040017287A (ko) 2004-02-26
MXPA04000210A (es) 2004-07-23
CN101607913B (zh) 2012-07-04
US8852550B2 (en) 2014-10-07
ES2250671T3 (es) 2006-04-16
CA2450690C (en) 2009-03-24
US7597875B2 (en) 2009-10-06
CA2450690A1 (en) 2003-01-23
NO334093B1 (no) 2013-12-09
CN1527727A (zh) 2004-09-08
JP2005500325A (ja) 2005-01-06
WO2003006070A2 (en) 2003-01-23
CN100509061C (zh) 2009-07-08
DE60206272T2 (de) 2006-07-13
NO20035597L (no) 2004-03-03
EP1404377A2 (en) 2004-04-07
BR0210965A (pt) 2004-06-08
WO2003006070A3 (en) 2003-08-21
AU2002317317B2 (en) 2005-11-17
ATE304866T1 (de) 2005-10-15
CN101607913A (zh) 2009-12-23
KR100892009B1 (ko) 2009-04-07
CN101538313A (zh) 2009-09-23
HK1064585A1 (en) 2005-02-04
HUP0401265A3 (en) 2005-11-28
HU228850B1 (en) 2013-06-28
NO20035597D0 (no) 2003-12-16
JP5015409B2 (ja) 2012-08-29
DE60206272D1 (de) 2005-10-27
US20100040542A1 (en) 2010-02-18
RU2298012C2 (ru) 2007-04-27
US20040258619A1 (en) 2004-12-23
RU2003137592A (ru) 2005-05-20
GB0116815D0 (en) 2001-08-29
HUP0401265A2 (hu) 2004-09-28
CN101537190A (zh) 2009-09-23
EP1404377B1 (en) 2005-09-21
ZA200400143B (en) 2004-12-29

Similar Documents

Publication Publication Date Title
GB0116815D0 (en) Improved chelator conjugates
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
PL1791571T3 (pl) Radiofluorowane peptydy
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
HK1068626A1 (en) Chemical compounds
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
GB0105224D0 (en) Improved peptide-chelate conjugates
TW200732345A (en) Niobium compound
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
PL352104A1 (en) Oral composition containing perlite
ATE242763T1 (de) Methoximinophenylessigsäureamide
MXPA05008108A (es) Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
BG103595A (en) Metoprolol compound and methods for its preparation
TW200519206A (en) Methods for producing novel medaka and novel medaka
ITVR20020030A1 (it) Miscela per polvere di saldatura, nonché procedimento per l'impiego di detta miscela.